# Darrin Miles

> Darrin Miles is the President and CEO of Nested Therapeutics, a Cambridge, Massachusetts precision oncology company that launched in 2022 with $125 million in financing to hunt for cancer-driving mutations hiding in plain sight. A commercialization leader with more than two decades in healthcare, Miles spent 14 years at Genentech shepherding landmark cancer brands and later served as Chief Commercial Officer at Agios Pharmaceuticals, where he helped bring the first mutant-IDH therapies to acute myeloid leukemia patients. At Nested, he is translating computational biophysics, genomics, and chemical biology into drugs aimed at targets the rest of the field calls undruggable.

- **Role:** President & Chief Executive Officer at Nested Therapeutics
- **Organizations:** Nested Therapeutics, Agios Pharmaceuticals, Genentech
- **Nationality:** American
- **Education:** B.S. in Applied Economics, Cornell University
- **Known for:** Helped advance and commercialize landmark oncology therapies at Genentech (Herceptin, Tarceva, Perjeta) and Agios (IDHIFA, TIBSOVO), Led the precision oncology program management function that brought the first mutant-IDH therapies to acute myeloid leukemia patients, Took the helm of Nested Therapeutics, which raised a $90M Series A (led by Goldman Sachs Asset Management) bringing total financing to $125M

## Career timeline

- **1990s-2000s** — Joined Genentech, beginning a 14-year tenure across global program leadership, marketing, sales management, and market access
- **2000s** — Supported commercialization of major Genentech cancer brands including Herceptin, Perjeta, Tarceva and Rituxan
- **2010s** — Joined Agios Pharmaceuticals, eventually serving as Chief Commercial Officer leading oncology and rare disease commercialization
- **2010s** — Led precision oncology program management through the development and approval of IDHIFA and TIBSOVO for mutant-IDH acute myeloid leukemia
- **2022** — Named President & CEO of Nested Therapeutics, which launched publicly in October 2022 with $125M in total financing

## Achievements

- Helped advance and commercialize landmark oncology therapies at Genentech (Herceptin, Tarceva, Perjeta) and Agios (IDHIFA, TIBSOVO)
- Led the precision oncology program management function that brought the first mutant-IDH therapies to acute myeloid leukemia patients
- Took the helm of Nested Therapeutics, which raised a $90M Series A (led by Goldman Sachs Asset Management) bringing total financing to $125M
- Assembled a leadership and scientific team including co-founders Klaus Hoeflich and scientific founders Kevan Shokat and Arvin Dar

## Latest updates

- **2022-10** — Nested Therapeutics launched publicly with $125M in financing; Miles named President & CEO
- **2024-02** — Nested Therapeutics strengthened its Board of Directors with a new chair and directors

## Links

- Website: https://nestedtx.com
- LinkedIn: http://www.linkedin.com/in/darrinmiles

---

Profile page: https://yespress.io/darrin-miles
Published by YesPress — https://yespress.io
Last updated: 2026-06-13